Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial - Powles, T; Burotto, M; Escudier, B (ESMO Open, 2024)